Skip to main content

All products are sold strictly for laboratory research use only. Not for human or veterinary consumption, diagnosis, or treatment. Not approved by the FDA.

Research Use Only
RIBOCORE
Browse ProductsMost PopularPurity ReportsResearchResearch Use OnlySupport
0
RIBOCORE

Research-use-only peptides, compounds, and analytical documentation for qualified laboratories and institutions.

Products

  • Catalog
  • Most Popular
  • New Releases
  • Bundles

Trust

  • Purity Reports
  • Quality & Testing
  • Research Blog
  • Research Use Only
  • Shipping Policy
  • Discreet Delivery
  • Guarantee
  • Support Center

Stay Updated

Join our researcher list for batch alerts and purity report updates.

© 2026 RIBOCORE ANALYTICAL. ALL PRODUCTS SOLD STRICTLY FOR LABORATORY RESEARCH USE ONLY.
PrivacyTerms of ServiceShippingResearch Use OnlyPurity Reports

Search results for "CAS number"

Found 53 products

Categories

  • GLP-1 & Weight Management(22)
  • Recovery & Healing(7)
  • Growth Hormone Peptides(13)
  • Anti-Aging & Wellness(20)
  • Supplies & Accessories(24)
  • Bundles(4)

Brand

53 results

Cagrilintide (5mg) / Tirz (10mg)
99.4% Purity
In Stock
-25%

Cagrilintide (5mg) / Tirz (10mg)

  • Triple-Receptor Agonist: Combines amylin, GIP, and GLP-1 pathways in one formulation
  • Multi-Pathway Engagement: Three independent satiety and metabolic control mechanisms
  • Research Blend: 5mg Cagrilintide + 10mg Tirzepatide, ≥98% purity each component
$199.00

$149.00

Thymosin Alpha-1
99.4% Purity
In Stock

Thymosin Alpha-1

  • 28-Amino Acid Immunomodulator: N-terminal fragment of prothymosin alpha (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN), originally isolated from thymus 1977, 3,000+ publications, thymalfasin (Zadaxin) approved in 35+ countries
  • Pleiotropic Immune Activation: TLR2/3/4/7/9 agonist, dendritic cell activation, T-cell maturation (CD4+/CD8+), Th1 polarization (IL-2/IL-12/IFN-γ↑), NK cell enhancement, PD-1/Tim-3 exhaustion marker reduction
  • Clinical Status: FDA orphan drug (DiGeorge anomaly, melanoma, hepatitis B, HCC), China approved for hepatitis B/HCC, COVID-19 mortality reduction (11.11% vs 30.00%, Liu et al. 2020), sepsis meta-analysis 41% mortality reduction

$49.00

TB-500 (Thymosin Beta-4) (43aa)
99.4% Purity
In Stock

TB-500 (Thymosin Beta-4) (43aa)

  • Thymosin Beta-4 Derivative: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH), derived from naturally occurring thymosin beta-4 (70-80% of beta-thymosins), 2,000+ publications, N-terminal acetylation for enhanced stability
  • Multi-Pathway Regeneration: G-actin sequestration (Kd 0.5-0.7 μM), cell migration promotion, VEGF upregulation via Wnt/β-catenin/Lef-1, angiogenesis, PI3K/Akt/eNOS survival pathway, anti-fibrotic via TGF-β1 suppression
  • Clinical Status: No FDA-approved human drug, all therapeutic data preclinical (wound healing, cardiac repair, pulmonary fibrosis, Alzheimer's neuroprotection), extensive safety profile in animal models

$36.40

SLU-PP-332 Capsules (250mcg) 100 Count
99.4% Purity
In Stock

SLU-PP-332 Capsules (250mcg) 100 Count

  • Pan-ERR Agonist Exercise Mimetic: Hydrazone small molecule (E)-4-hydroxy-N'-(naphthalen-2-ylmethylene)benzohydrazide, Saint Louis University design, activates ERRalpha/beta/gamma (EC50 98/230/430 nM), 10+ publications, all preclinical
  • Multi-System Metabolic Reprogramming: 70% increased endurance, 12% body weight loss, mitochondrial biogenesis via PGC-1alpha/AMPK/TFAM cascade, type IIa muscle fiber conversion, 25% increased fatty acid oxidation, reverses age-related kidney dysfunction
  • Clinical Status: No human trials (as of Feb 2026), all data from mouse models, well-tolerated in 8-week studies, successor compound SLU-PP-915 with improved oral bioavailability developed 2026

$89.00

Rad140 Capsules (15mg) 60 Count
99.4% Purity
In Stock
-17%

Rad140 Capsules (15mg) 60 Count

  • Nonsteroidal SARM: Benzonitrile-oxadiazole scaffold with AR binding Ki 7 nM (comparable to DHT 10 nM), first described 2011, tissue-selective levator ani vs. prostate activity, oral bioavailability 27-75%
  • Clinical Development: Phase 1 ER+/HER2- breast cancer (MTD 100 mg/day, t½ 44.7 hours), active Phase 1/2 trial (NCT05573126, Ellipses Pharma EP0062), discontinued for sarcopenia indications
  • Safety Warnings: Dose-limiting hepatotoxicity (AST 59.1%, ALT 45.5%), cholestatic liver injury case reports, cardiotoxicity (myocarditis/myopericarditis), HPG axis suppression, WADA prohibited S1.2, not approved for medical use
$119.00

$99.00

PT-141 10mg
99.4% Purity
In Stock

PT-141 10mg

  • FDA-Approved Melanocortin Agonist: Cyclic heptapeptide MC3R/MC4R agonist, approved June 2019 (Vyleesi) for premenopausal HSDD, 100+ publications, first melanocortin therapeutic for sexual function
  • CNS Mechanism: Crosses blood-brain barrier, activates hypothalamic MC4R in mPOA triggering dopamine release, melanocortin-dopamine integration, mesolimbic reward pathway modulation
  • Clinical Development: 43 completed trials with 3,500+ subjects, Phase 3 RECONNECT (n=1,267) showed +0.35 desire improvement, 58% vs 36% responder rates, well-characterized safety profile

$33.25

Pep Pen Carrying Case
99.4% Purity
In Stock
-10%

Pep Pen Carrying Case

  • Profile: Laboratory supply for research peptide applications
  • Quality: >=95% Purity (HPLC Verified)
$10.00

$8.99

Oxytocin 10mg (6000 IU)
99.4% Purity
In Stock

Oxytocin 10mg (6000 IU)

  • Cyclic nonapeptide hormone with characteristic Cys1-Cys6 disulfide bridge, synthesized by Nobel laureate Vincent du Vigneaud (1954)
  • OXTR agonist activating Gq/11-PLC-IP3/DAG cascade; modulates social cognition, stress axis, metabolism, and cardiovascular function
  • Validated in ~25,000 publications spanning social neuroscience, reproductive physiology, psychiatry, metabolic medicine, and cardiology

$19.00

MK-677 Capsules (25mg) 60 Count
99.4% Purity
In Stock

MK-677 Capsules (25mg) 60 Count

  • Oral GH Secretagogue: Non-peptide ghrelin mimetic (C₂₇H₃₆N₄O₅S), >60% bioavailability
  • GHS-R1a Agonist: High affinity (pKi = 8.14, EC50 = 1.3 nM), sustained GH-IGF-1 elevation
  • Clinical Evidence: 30-year history, >1,000 subjects, Phase 3 development for pediatric GHD

$99.00

KLOW (80mg)
99.4% Purity
In Stock

KLOW (80mg)

  • Quad-Peptide Blend: BPC-157 10mg + TB-500 10mg + GHK-Cu 50mg + KPV 10mg (80mg total)
  • Enhanced Anti-Inflammatory: KPV addition for NF-κB pathway inhibition and cytokine control
  • Comprehensive Regeneration: Cytoprotection, angiogenesis, collagen synthesis, and inflammation modulation

$110.00

IGF-1 LR3 (1mg)
99.4% Purity
In Stock

IGF-1 LR3 (1mg)

  • 83-amino acid analog with enhanced potency (~3x native IGF-1) and extended half-life (20-30 hours)
  • Engineered for reduced IGFBP binding, allowing sustained IGF-1R activation without sequestration
  • Validated in 22+ publications across cardiovascular, fetal growth, gastrointestinal, and cell culture research

$59.00

L-Glutathione 600mg
99.4% Purity
In Stock

L-Glutathione 600mg

  • Master Antioxidant Tripeptide: L-γ-Glu-L-Cys-Gly sequence, ≥98% purity
  • Cellular Redox Homeostasis: Primary intracellular thiol buffer (0.5-10 mM)
  • Phase II Detoxification: GST-mediated conjugation and xenobiotic metabolism studies

$60.00

Showing 1 to 12 of 53 results

12345